Orion Corporation’s partner Bayer submits sNDA to US FDA for oral androgen receptor inhibitor darolutamide: Espoo, Finland Saturday, September 28, 2024, 15:00 Hrs [IST] Finnish ...
Zacks.com on MSN19h
Bayer Submits Application for Label Expansion of Prostate Cancer DrugBayer BAYRY announced the submission of a supplemental new drug application (sNDA) to the FDA for darolutamide. The sNDA is ...
A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery ...
The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.
A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery ...
Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic ...
Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of ...
The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without ...
1d
German pharmaceutical company Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Thursday the submission of a supplemental new drug ...
This report is a review of recent and emerging trends that promise to make radiation oncology for prostate cancer more ...
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback